Lantheus Holdings, Inc. (NASDAQ:LNTH) Position Boosted by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC boosted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.1% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,691 shares of the medical equipment provider’s stock after acquiring an additional 139 shares during the period. Nisa Investment Advisors LLC’s holdings in Lantheus were worth $653,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of LNTH. Linden Thomas Advisory Services LLC raised its holdings in Lantheus by 2.9% during the first quarter. Linden Thomas Advisory Services LLC now owns 22,569 shares of the medical equipment provider’s stock worth $2,203,000 after purchasing an additional 630 shares in the last quarter. Envestnet Asset Management Inc. grew its position in Lantheus by 5.7% during the 1st quarter. Envestnet Asset Management Inc. now owns 124,186 shares of the medical equipment provider’s stock worth $12,121,000 after purchasing an additional 6,659 shares in the last quarter. Concurrent Investment Advisors LLC purchased a new position in Lantheus during the 1st quarter worth approximately $350,000. Moody Aldrich Partners LLC grew its position in Lantheus by 0.6% during the 1st quarter. Moody Aldrich Partners LLC now owns 36,205 shares of the medical equipment provider’s stock worth $3,534,000 after purchasing an additional 217 shares in the last quarter. Finally, Principal Financial Group Inc. grew its holdings in shares of Lantheus by 40.2% during the 1st quarter. Principal Financial Group Inc. now owns 258,495 shares of the medical equipment provider’s stock valued at $25,229,000 after acquiring an additional 74,149 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Analysts Set New Price Targets

LNTH has been the subject of a number of research reports. Wall Street Zen raised Lantheus from a “hold” rating to a “buy” rating in a research report on Thursday, May 8th. B. Riley cut their price objective on shares of Lantheus from $122.00 to $109.00 and set a “buy” rating for the company in a research report on Monday, June 23rd. Finally, Truist Financial cut their price objective on shares of Lantheus from $127.00 to $117.00 and set a “buy” rating for the company in a research report on Thursday, May 8th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $131.20.

Insider Transactions at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of the firm’s stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the transaction, the director directly owned 318,650 shares of the company’s stock, valued at approximately $24,481,879.50. This trade represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.00% of the company’s stock.

Lantheus Stock Down 2.2%

NASDAQ LNTH opened at $81.26 on Wednesday. The firm has a market cap of $5.62 billion, a PE ratio of 23.09 and a beta of 0.12. Lantheus Holdings, Inc. has a one year low of $73.11 and a one year high of $126.89. The stock’s 50 day simple moving average is $79.29 and its 200 day simple moving average is $89.79. The company has a debt-to-equity ratio of 0.49, a current ratio of 5.74 and a quick ratio of 5.46.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). The company had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a net margin of 16.55% and a return on equity of 36.99%. Lantheus’s revenue for the quarter was up .8% compared to the same quarter last year. During the same period last year, the company earned $1.69 earnings per share. As a group, sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.